GenMark Diagnostics (GNMK) CFO Scott Mendel Sells 1,904 Shares

GenMark Diagnostics (NASDAQ:GNMK) CFO Scott Mendel sold 1,904 shares of the company’s stock in a transaction dated Monday, May 21st. The shares were sold at an average price of $6.91, for a total transaction of $13,156.64. Following the sale, the chief financial officer now directly owns 236,546 shares of the company’s stock, valued at approximately $1,634,532.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Scott Mendel also recently made the following trade(s):

  • On Tuesday, May 15th, Scott Mendel sold 1,218 shares of GenMark Diagnostics stock. The shares were sold at an average price of $6.60, for a total transaction of $8,038.80.
  • On Wednesday, May 2nd, Scott Mendel sold 218 shares of GenMark Diagnostics stock. The shares were sold at an average price of $6.18, for a total transaction of $1,347.24.
  • On Monday, February 26th, Scott Mendel sold 6,275 shares of GenMark Diagnostics stock. The shares were sold at an average price of $4.17, for a total value of $26,166.75.

Shares of GenMark Diagnostics traded down $0.12, reaching $6.92, during mid-day trading on Tuesday, MarketBeat Ratings reports. 144,900 shares of the company traded hands, compared to its average volume of 381,385. The company has a market cap of $385.12 million, a PE ratio of -5.72 and a beta of 0.55. The company has a current ratio of 2.79, a quick ratio of 2.45 and a debt-to-equity ratio of 0.24. GenMark Diagnostics has a 52 week low of $3.63 and a 52 week high of $13.50.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings data on Tuesday, May 1st. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. The company had revenue of $20.65 million during the quarter, compared to the consensus estimate of $17.12 million. GenMark Diagnostics had a negative return on equity of 77.35% and a negative net margin of 97.90%. equities research analysts predict that GenMark Diagnostics will post -0.77 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. MetLife Investment Advisors LLC bought a new position in GenMark Diagnostics in the 1st quarter worth approximately $143,000. Wrapmanager Inc. boosted its stake in GenMark Diagnostics by 121.3% in the 4th quarter. Wrapmanager Inc. now owns 39,547 shares of the medical equipment provider’s stock worth $165,000 after purchasing an additional 21,679 shares during the period. UBS Asset Management Americas Inc. boosted its stake in GenMark Diagnostics by 111.1% in the 4th quarter. UBS Asset Management Americas Inc. now owns 49,400 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 26,000 shares during the period. OLD National Bancorp IN boosted its stake in GenMark Diagnostics by 120.6% in the 4th quarter. OLD National Bancorp IN now owns 49,765 shares of the medical equipment provider’s stock worth $208,000 after purchasing an additional 27,208 shares during the period. Finally, Fairpointe Capital LLC bought a new position in GenMark Diagnostics in the 4th quarter worth approximately $220,000.

A number of research analysts recently issued reports on GNMK shares. BidaskClub upgraded GenMark Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 27th. Canaccord Genuity cut their price objective on GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, February 28th. BTIG Research set a $11.00 price objective on GenMark Diagnostics and gave the company a “buy” rating in a research note on Wednesday, May 2nd. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of GenMark Diagnostics in a research note on Tuesday, April 24th. Finally, Zacks Investment Research upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Thursday, January 25th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $10.60.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply